Palforzia, the first and only oral immunotherapy the Food and Drug Administration ever approved for peanut allergy, left the market on July 31. The manufacturer's notice from Stallergenes Greer states that the voluntary discontinuation is not related to product safety, quality or efficacy.
The product treated confirmed peanut allergy in children ages 1 through 17. Under FDA labeling, it was indicated to reduce the severity of allergic reactions, including anaphylaxis, following accidental exposure, and was to be used alongside a peanut-avoidant diet. It was never a cure, nor was it for treating a reaction in progress. The restricted access program that governed its use, a Risk Evaluation and Mitigation Strategy, is being wound down along with the product.
For families in the middle of a dosing schedule, the practical question is not why a company made a business decision. It is what happens to a child who has spent months building tolerance and now has no approved product to continue with.
The Reason a Landmark Product Failed Commercially
Palforzia received FDA approval in January 2020, initially for ages 4 through 17, with the age range later expanded to include ages down to 1. It was developed by Aimmune Therapeutics, acquired by Nestle Health Science in a deal valued at over $2 billion, and sold to Stallergenes Greer in September 2023.
The company told Healio that complex administrative and dosing requirements contributed to limited adoption in clinical practice. Several structural problems compounded that. The launch coincided with the start of the COVID-19 pandemic, which paused in-office dose escalations for roughly a year. The restricted access program added to the clinic's burden. Payer coverage proved difficult to secure.
Robert Wood, a Johns Hopkins physician who studies oral immunotherapy outcomes in children with food allergy, offered a blunt assessment of the practical fallout. He told HCPLive that the practice of OIT has continued, and that few families will miss Palforzia as an option because those who want peanut oral immunotherapy will continue to do it with products bought at the grocery store.
The Options That Remain and the Certainty They Lack
The treatment landscape did not empty out, but it changed character in a way worth stating precisely.
Office-based oral immunotherapy continues. Some allergists prepare non-pharmaceutical-grade peanut products, often measured peanut flour or powdered peanut products, using established protocols under medical supervision. The Allergy and Asthma Network notes that these approaches are not FDA-approved, which means dosing is not standardized across practices and insurance coverage varies.
Omalizumab, sold as Xolair, is now the only FDA-approved therapy for food allergy. It was approved in 2024 for adults and children aged 1 and older with one or more IgE-mediated food allergies, and reduces the risk of reactions after accidental exposure without curing the allergy. Wood described treatment selection as now hinging heavily on how many foods a patient reacts to, since multi-allergen oral immunotherapy carries a higher side-effect burden than single-food treatment, and said his team increasingly pairs omalizumab with staged food introduction.
Sublingual immunotherapy and the epicutaneous peanut patch remain investigational and are not FDA-approved, though the patch has reported positive results in late-stage trials. Additional candidates are in development, including an anti-IgE therapy in early trials that GSK acquired through its purchase of RAPT Therapeutics, which would require dosing every 12 weeks if it succeeds. None of that helps a family this month.
The practical consequence of losing the approved product is not that treatment disappeared. It is that the standardization disappeared. A pharmaceutical-grade product carried pre-measured doses, a documented risk-benefit profile from registration trials, and a common reference point across clinics. Office-based protocols are well established and widely used, but a dose at one practice is not necessarily identical to a dose at another, and families comparing options now have to ask questions that the label used to answer for them.
The Families Carrying the Most Uncertainty
Three groups are affected differently, and lumping them together produces bad advice.
Children who completed dosing and reached maintenance face the question of how to sustain that maintenance dose without the approved product, which is generally answered by transitioning to a measured store-bought peanut product under an allergist's supervision. Children still in the up-dosing phase face the harder problem because they have built partial tolerance on a standardized product and now need a supervised transition to a differently formulated one. Families who were on a waiting list to begin never started and now need a fresh conversation about whether office-based treatment, omalizumab, or continued strict avoidance fits their situation.
The most important instruction applies to all three. Do not stop, restart, or change a dose on your own. Abrupt discontinuation can reduce tolerance that was built over months, and resuming after a gap is not simply a matter of picking up where a child left off. That decision should be made by a board-certified allergist who knows the child's history.
Everything else about peanut allergy management continues unchanged. Strict avoidance remains necessary; two epinephrine devices should be carried at all times, and emergency action plans at school and day care should be up to date. Oral immunotherapy in any form reduces the risk of accidental exposure. It does not permit eating peanuts freely, and no product on the market ever did.
Signs of a severe reaction include difficulty breathing, throat tightness, widespread hives, vomiting, dizziness, a sudden drop in blood pressure, or collapse. Those require immediate epinephrine and emergency care.
What remains unknown is whether any manufacturer will seek approval for a replacement standardized product, how insurers will treat office-based protocols without an approved comparator, and when investigational options might reach the market. MedicalDaily will report on any new FDA actions regarding food allergies.
Key Questions Answered
When did Palforzia leave the market? Commercialization ended July 31, 2026, with production winding down in phases. The product is no longer available for commercial distribution in the United States.
Was it recalled for safety? No. The manufacturer states the voluntary discontinuation is not related to product safety, quality, or efficacy and cites complex administrative and dosing requirements limiting adoption.
Who was it approved for? Children with confirmed peanut allergy, ages 1 through 17. It was first approved for ages 4 through 17, and the range was later expanded.
Should my child stop taking their remaining doses? Do not stop, restart, or change a dose without speaking to your allergist. Abrupt discontinuation can reduce tolerance built over months.
What options remain? Office-based oral immunotherapy using non-FDA-approved peanut products under supervision, and omalizumab, which is now the only FDA-approved food allergy therapy.
Is the peanut patch available? No. Epicutaneous immunotherapy and sublingual immunotherapy remain investigational and are not FDA-approved.
Does any treatment allow me to eat peanuts normally? No. These treatments reduce the severity of reactions to accidental exposure. Avoidance and carrying epinephrine remain necessary.
